Search

From Plans to Action: European Cancer Summit

From Plans to Action:  European Cancer Summit (Brussels-Hybrid, November 17-18, 2021) 
November 17- 18 marks the first anniversary of EHA’s membership to the European Cancer Organisation (ECO), as well as the event dates for the 2021 European Cancer Summit.

Read more

Code of Conduct

The guidelines below govern the publication of, and commentary on the EHA Hematology Hub. Please read through them before participating. 1. Abide by the rules that normally apply.

Read more

Guidelines for hematologists

For guidance regarding COVID-19, see FAQ by the EHA SWG on Infections

EHA creates clinical practice guidelines for diagnosis and treatment of hematologic diseases.

Read more

Parliament puts final stamp on the European Health Data Space

On April 24, the European Parliament gave its final endorsement to the regulation on the European Health Data Space (EHDS). The legislation was proposed in May 2022, and constitutes an important pillar of the (developing) European Health Union.

Read more

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Read more

Hematology 2.0: navigating the world of medical apps

Interview with Dr Alex Langridge, SpR, by Dr Nuno Borges, MBBS, MRes, on behalf of YoungEHA. Despite the controversy surrounding them, medical apps remain extremely popular and lucrative endeavors.

Read more

Sponsor prospectus

Dear Partner,

Welcome to the digital EHA Sponsor Prospectus 2024-2025. Over the past two years, the world of congresses, meetings, and education has drastically changed.

Read more

Revising the ICH Guidelines on Clinical Trials

The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.

Read more